Teva Pharmaceutical Industries Limited (NYSE:TEVA)‘s stock had its “hold” rating reaffirmed by equities research analysts at Mizuho in a report released on Wednesday. They currently have a $16.00 price objective on the stock. Mizuho’s target price indicates a potential upside of 2.04% from the company’s previous close.

Other analysts have also issued research reports about the company. Royal Bank Of Canada set a $38.00 target price on Teva Pharmaceutical Industries Limited and gave the stock a “buy” rating in a report on Friday, June 16th. Oppenheimer Holdings, Inc. set a $41.00 price objective on Teva Pharmaceutical Industries Limited and gave the company a “buy” rating in a report on Tuesday, June 27th. BidaskClub upgraded Teva Pharmaceutical Industries Limited from a “hold” rating to a “buy” rating in a report on Wednesday, July 5th. Vetr upgraded Teva Pharmaceutical Industries Limited from a “hold” rating to a “buy” rating and set a $32.27 price objective for the company in a report on Tuesday, July 11th. Finally, Credit Suisse Group AG set a $39.00 price objective on Teva Pharmaceutical Industries Limited and gave the company a “buy” rating in a report on Thursday, August 3rd. Five investment analysts have rated the stock with a sell rating, eighteen have given a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the company’s stock. The company has a consensus rating of “Hold” and a consensus price target of $28.72.

Teva Pharmaceutical Industries Limited (NYSE:TEVA) opened at 15.68 on Wednesday. Teva Pharmaceutical Industries Limited has a 52 week low of $15.22 and a 52 week high of $45.85. The firm’s 50-day moving average price is $16.94 and its 200-day moving average price is $26.89. The stock’s market cap is $15.93 billion. Teva Pharmaceutical Industries Limited also saw unusually large options trading on Wednesday. Traders acquired 29,656 put options on the company. This represents an increase of approximately 231% compared to the average daily volume of 8,957 put options.

Teva Pharmaceutical Industries Limited (NYSE:TEVA) last posted its earnings results on Thursday, August 3rd. The company reported $0.99 earnings per share for the quarter, missing analysts’ consensus estimates of $1.06 by ($0.07). The company had revenue of $5.69 billion for the quarter, compared to analysts’ expectations of $5.72 billion. Teva Pharmaceutical Industries Limited had a positive return on equity of 15.96% and a negative net margin of 25.18%. The firm’s quarterly revenue was up 12.9% on a year-over-year basis. During the same quarter in the prior year, the company earned $1.25 EPS. Equities analysts predict that Teva Pharmaceutical Industries Limited will post $4.28 earnings per share for the current fiscal year.

TRADEMARK VIOLATION NOTICE: “Teva Pharmaceutical Industries Limited (TEVA) Rating Reiterated by Mizuho” was originally reported by Watch List News and is the property of of Watch List News. If you are accessing this news story on another domain, it was copied illegally and republished in violation of United States & international copyright legislation. The original version of this news story can be viewed at https://www.watchlistnews.com/teva-pharmaceutical-industries-limited-teva-rating-reiterated-by-mizuho/1612260.html.

Several large investors have recently bought and sold shares of TEVA. Capital Research Global Investors grew its position in shares of Teva Pharmaceutical Industries Limited by 13.8% during the 2nd quarter. Capital Research Global Investors now owns 76,325,059 shares of the company’s stock valued at $2,535,518,000 after acquiring an additional 9,260,426 shares during the period. Franklin Resources Inc. grew its position in shares of Teva Pharmaceutical Industries Limited by 11.1% during the 2nd quarter. Franklin Resources Inc. now owns 66,796,897 shares of the company’s stock valued at $2,218,958,000 after acquiring an additional 6,685,844 shares during the period. FMR LLC grew its position in shares of Teva Pharmaceutical Industries Limited by 16.7% during the 2nd quarter. FMR LLC now owns 42,844,979 shares of the company’s stock valued at $1,423,310,000 after acquiring an additional 6,115,853 shares during the period. Capital World Investors grew its position in shares of Teva Pharmaceutical Industries Limited by 41.9% during the 2nd quarter. Capital World Investors now owns 11,068,200 shares of the company’s stock valued at $367,686,000 after acquiring an additional 3,268,200 shares during the period. Finally, Alliancebernstein L.P. grew its position in shares of Teva Pharmaceutical Industries Limited by 32.3% during the 2nd quarter. Alliancebernstein L.P. now owns 11,399,400 shares of the company’s stock valued at $378,688,000 after acquiring an additional 2,782,257 shares during the period. Hedge funds and other institutional investors own 56.77% of the company’s stock.

About Teva Pharmaceutical Industries Limited

Teva Pharmaceutical Industries Limited is a pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. The Company develops, manufactures and sells generic medicines in a range of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams.

Analyst Recommendations for Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Receive News & Ratings for Teva Pharmaceutical Industries Limited Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries Limited and related companies with Analyst Ratings Network's FREE daily email newsletter.